11/1
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/1
08:00 am
akba
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
Low
Report
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
10/23
08:18 am
akba
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Medium
Report
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
10/22
08:00 am
akba
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
High
Report
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
10/15
08:00 am
akba
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
Low
Report
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
10/10
08:00 am
akba
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
Low
Report
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
10/8
08:45 am
akba
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Low
Report
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
10/7
08:00 am
akba
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
Low
Report
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
10/1
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/25
09:34 am
akba
Gastrointestinal Collaboration and Licensing Agreements Analysis Report 2024 with Directory of 386 Deals Signed Since 2016 by the World's Leading Life Science Companies and Universities [Yahoo! Finance]
Low
Report
Gastrointestinal Collaboration and Licensing Agreements Analysis Report 2024 with Directory of 386 Deals Signed Since 2016 by the World's Leading Life Science Companies and Universities [Yahoo! Finance]
9/6
08:08 am
akba
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Medium
Report
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
9/5
08:00 am
akba
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
Low
Report
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
9/3
04:16 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/26
12:04 pm
akba
Here's Why You Should Consider Buying Akebia (AKBA) Stock [Yahoo! Finance]
Medium
Report
Here's Why You Should Consider Buying Akebia (AKBA) Stock [Yahoo! Finance]
8/26
08:00 am
akba
Akebia Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Akebia Therapeutics to Present at Upcoming Investor Conferences
8/12
08:03 am
akba
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $6.00 to $7.50. They now have a "buy" rating on the stock.
High
Report
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $6.00 to $7.50. They now have a "buy" rating on the stock.
8/10
09:37 am
akba
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets [Yahoo! Finance]
Medium
Report
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets [Yahoo! Finance]
8/10
01:49 am
akba
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript [Seeking Alpha]
8/8
07:00 am
akba
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights